Revenue
2018
2023
2024
2025
Neurogene Inc. (NGNE)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $925,000 | $0 | — | — | — | — | $25.0M | — | — | — | — | — | — |
| Research & development | $75.0M | $60.9M | $44.4M | $47.5M | $39.2M | $24.3M | $4.4M | $41.8M | $36.3M | $28.4M | $15.8M | $18.1M | $7.6M | $6.0M |
| Operating expenses | $103.3M | $83.5M | $55.6M | $56.5M | $60.7M | — | $71.0M | $57.6M | $51.1M | $37.6M | $21.3M | $22.4M | $9.4M | $7.7M |
| Operating income | −$103.3M | −$82.6M | −$55.6M | −$56.5M | −$60.7M | −$33.7M | −$71.0M | −$32.6M | −$51.1M | −$37.6M | — | — | — | — |
| EBITDAderived | −$100.3M | −$79.4M | −$52.3M | −$53.3M | −$59.4M | −$32.9M | −$70.6M | −$32.3M | −$50.8M | — | — | — | — | — |
| Net income | −$90.4M | −$75.1M | −$36.3M | −$55.2M | −$60.7M | −$33.3M | −$69.4M | −$31.6M | −$50.2M | −$37.0M | −$21.9M | −$24.0M | −$8.7M | −$7.7M |
| Basic EPSper diluted share | -$4.24 | -$4.28 | — | -$1.04 | -$1.10 | -$0.64 | -$2.57 | -$1.34 | -$2.14 | -$1.96 | -$1.73 | -$2.75 | -$49.52 | -$40.23 |
| Diluted EPSper diluted share | -$4.24 | -$4.28 | — | -$1.04 | -$1.10 | -$0.64 | -$2.57 | -$1.34 | -$2.14 | -$1.96 | -$1.73 | -$2.75 | -$49.52 | -$40.23 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 6, 2026Form 4 · 10b5-1 | Cvijic Christine MikailPresident and CFO | SellCommon Stock | 4.8K | $32.44 | $155.7K | 93.6K |
| May 6, 2026Form 4 · 10b5-1 | Cvijic Christine MikailPresident and CFO | SellCommon Stock | 4.8K | $30.07 | $144.3K | 98.4K |
| Mar 26, 2026Form 4 · 10b5-1 | Jordan JulieChief Medical Officer | SellCommon Stock | 828 | $21.89 | $18.1K | 12.5K |
| Mar 26, 2026Form 4 · 10b5-1 | McMinn RachelChief Executive Officer | SellCommon Stock | 3.4K | $22.07 | $74.0K | 1.34M |
| Mar 26, 2026Form 4 · 10b5-1 | Cvijic Christine MikailPresident and CFO | SellCommon Stock | 2.6K | $21.62 | $55.3K | 103.2K |